Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Aug 1;102(3):473–482. doi: 10.1172/JCI3741

CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses.

B R Blazar 1, P A Taylor 1, R J Noelle 1, D A Vallera 1
PMCID: PMC508907  PMID: 9691083

Abstract

A major goal of the transplant field is to tolerize donor T cells to prevent graft-versus-host disease (GVHD) (1). We describe an ex vivo approach in which the blockade of CD40 ligand (CD40L:CD154):CD40 interactions, a pathway required for optimal T cell expansion, induces donor CD4(+) T cells to become tolerant to host alloantigens (2). High doses of tolerized cells did not cause GVHD lethality in vivo. T cells had intact responses to antigens not present during tolerization. Tolerance was long lived and not readily reversible in vivo. These data have significant implications for the use of tolerization approaches to prevent human GVHD.

Full Text

The Full Text of this article is available as a PDF (274.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banchereau J., Bazan F., Blanchard D., Brière F., Galizzi J. P., van Kooten C., Liu Y. J., Rousset F., Saeland S. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881–922. doi: 10.1146/annurev.iy.12.040194.004313. [DOI] [PubMed] [Google Scholar]
  2. Blazar B. R., Korngold R., Vallera D. A. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev. 1997 Jun;157:79–109. doi: 10.1111/j.1600-065x.1997.tb00976.x. [DOI] [PubMed] [Google Scholar]
  3. Blazar B. R., Taylor P. A., Panoskaltsis-Mortari A., Buhlman J., Xu J., Flavell R. A., Korngold R., Noelle R., Vallera D. A. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 1997 Jan 1;158(1):29–39. [PubMed] [Google Scholar]
  4. Buhlmann J. E., Foy T. M., Aruffo A., Crassi K. M., Ledbetter J. A., Green W. R., Xu J. C., Shultz L. D., Roopesian D., Flavell R. A. In the absence of a CD40 signal, B cells are tolerogenic. Immunity. 1995 Jun;2(6):645–653. doi: 10.1016/1074-7613(95)90009-8. [DOI] [PubMed] [Google Scholar]
  5. Chen W., Murphy B., Waaga A. M., Willett T. A., Russell M. E., Khoury S. J., Sayegh M. H. Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo. Transplantation. 1996 Sep 27;62(6):705–710. doi: 10.1097/00007890-199609270-00001. [DOI] [PubMed] [Google Scholar]
  6. Durie F. H., Aruffo A., Ledbetter J., Crassi K. M., Green W. R., Fast L. D., Noelle R. J. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest. 1994 Sep;94(3):1333–1338. doi: 10.1172/JCI117453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Durie F. H., Fava R. A., Foy T. M., Aruffo A., Ledbetter J. A., Noelle R. J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 1993 Sep 3;261(5126):1328–1330. doi: 10.1126/science.7689748. [DOI] [PubMed] [Google Scholar]
  8. Falkenburg J. H., Smit W. M., Willemze R. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol Rev. 1997 Jun;157:223–230. doi: 10.1111/j.1600-065x.1997.tb00985.x. [DOI] [PubMed] [Google Scholar]
  9. Fowler D. H., Kurasawa K., Husebekk A., Cohen P. A., Gress R. E. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol. 1994 Feb 1;152(3):1004–1013. [PubMed] [Google Scholar]
  10. Grewal I. S., Xu J., Flavell R. A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 1995 Dec 7;378(6557):617–620. doi: 10.1038/378617a0. [DOI] [PubMed] [Google Scholar]
  11. Holländer G. A., Castigli E., Kulbacki R., Su M., Burakoff S. J., Gutierrez-Ramos J. C., Geha R. S. Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4994–4998. doi: 10.1073/pnas.93.10.4994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jenkins M. K., Schwartz R. H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987 Feb 1;165(2):302–319. doi: 10.1084/jem.165.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kearney E. R., Pape K. A., Loh D. Y., Jenkins M. K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity. 1994 Jul;1(4):327–339. doi: 10.1016/1074-7613(94)90084-1. [DOI] [PubMed] [Google Scholar]
  14. Krenger W., Snyder K. M., Byon J. C., Falzarano G., Ferrara J. L. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995 Jul 15;155(2):585–593. [PubMed] [Google Scholar]
  15. Lee R. S., Grusby M. J., Glimcher L. H., Winn H. J., Auchincloss H., Jr Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med. 1994 Mar 1;179(3):865–872. doi: 10.1084/jem.179.3.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Liu C. P., Kappler J. W., Marrack P. Thymocytes can become mature T cells without passing through the CD4+ CD8+, double-positive stage. J Exp Med. 1996 Nov 1;184(5):1619–1630. doi: 10.1084/jem.184.5.1619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Liu Z., Colovai A. I., Tugulea S., Reed E. F., Fisher P. E., Mancini D., Rose E. A., Cortesini R., Michler R. E., Suciu-Foca N. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest. 1996 Sep 1;98(5):1150–1157. doi: 10.1172/JCI118898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Liu Z., Sun Y. K., Xi Y. P., Maffei A., Reed E., Harris P., Suciu-Foca N. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med. 1993 Jun 1;177(6):1643–1650. doi: 10.1084/jem.177.6.1643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mackall C. L., Gress R. E. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev. 1997 Jun;157:61–72. doi: 10.1111/j.1600-065x.1997.tb00974.x. [DOI] [PubMed] [Google Scholar]
  20. Noelle R. J., Roy M., Shepherd D. M., Stamenkovic I., Ledbetter J. A., Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6550–6554. doi: 10.1073/pnas.89.14.6550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Parker D. C., Greiner D. L., Phillips N. E., Appel M. C., Steele A. W., Durie F. H., Noelle R. J., Mordes J. P., Rossini A. A. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9560–9564. doi: 10.1073/pnas.92.21.9560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Parkman R., Weinberg K. I. Immunological reconstitution following bone marrow transplantation. Immunol Rev. 1997 Jun;157:73–78. doi: 10.1111/j.1600-065x.1997.tb00975.x. [DOI] [PubMed] [Google Scholar]
  23. Sayegh M. H., Carpenter C. B. Role of indirect allorecognition in allograft rejection. Int Rev Immunol. 1996;13(3):221–229. doi: 10.3109/08830189609061749. [DOI] [PubMed] [Google Scholar]
  24. Schmid I., Uittenbogaart C. H., Keld B., Giorgi J. V. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J Immunol Methods. 1994 Apr 15;170(2):145–157. doi: 10.1016/0022-1759(94)90390-5. [DOI] [PubMed] [Google Scholar]
  25. Sha W. C., Nelson C. A., Newberry R. D., Kranz D. M., Russell J. H., Loh D. Y. Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature. 1988 Nov 3;336(6194):73–76. doi: 10.1038/336073a0. [DOI] [PubMed] [Google Scholar]
  26. Sprent J., Miller J. F. Thoracic duct lymphocytes from nude mice: migratory properties and life-span. Eur J Immunol. 1972 Aug;2(4):384–387. doi: 10.1002/eji.1830020420. [DOI] [PubMed] [Google Scholar]
  27. Sprent J., Schaefer M., Hurd M., Surh C. D., Ron Y. Mature murine B and T cells transferred to SCID mice can survive indefinitely and many maintain a virgin phenotype. J Exp Med. 1991 Sep 1;174(3):717–728. doi: 10.1084/jem.174.3.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sprent J., Surh C. D., Agus D., Hurd M., Sutton S., Heath W. R. Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells. J Exp Med. 1994 Jul 1;180(1):307–317. doi: 10.1084/jem.180.1.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Theobald M., Nierle T., Bunjes D., Arnold R., Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med. 1992 Dec 3;327(23):1613–1617. doi: 10.1056/NEJM199212033272301. [DOI] [PubMed] [Google Scholar]
  30. Vella J. P., Vos L., Carpenter C. B., Sayegh M. H. Role of indirect allorecognition in experimental late acute rejection. Transplantation. 1997 Dec 27;64(12):1823–1828. doi: 10.1097/00007890-199712270-00033. [DOI] [PubMed] [Google Scholar]
  31. Weisdorf D. J., Anderson P. M., Blazar B. R., Uckun F. M., Kersey J. H., Ramsay N. K. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study. Transplantation. 1993 Jan;55(1):61–66. doi: 10.1097/00007890-199301000-00012. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES